Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated with better clinical outcomes. Triplet therapy that includes darolutamide vs ...

Darolutamide plus ADT vs placebo plus ADT improves oncologic outcomes in patients with mHSPC regardless of disease volume, although the benefit is more pronounced among patients with low-volume ...

Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23). This is an ASCO Meeting Abstract from ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England ...

Now, men with this diagnosis can live for a decade or longer with new treatments, including drugs such as abiraterone, enzalutamide, apalutamide and darolutamide that block androgen receptors in ...

The trial will enroll 80 patients and aims to determine if opaganib can enhance the effectiveness of darolutamide, a treatment for prostate cancer which often develops resistance to standard care.

Insulin icodec for treating type 2 diabetes [ID6175] Technology appraisal guidance TBC Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating ...